CoChat

Saving 100 million lives by improving global treatment of hypertension and reducing cardiovascular disease risk factors

Open access
Frieden, Thomas R., Jaffe, Marc G. · 2018 · The Journal of Clinical Hypertension
Cited by 109

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Each year, cardiovascular disease (CVD) kills more than 18 million people worldwide, a third of all global deaths, with this proportion expected to increase further.1 High blood pressure is the leading cause of CVD and it will kill nearly 10 million people this year—half of the CVD total and more people than all infectious diseases combined.2 CVD rates are in higher and the burden on younger populations is greater in lower- than in higher-income countries. Four in five CVD-related deaths occur in low- or middle-income countries, and a higher proportion of these deaths occur in people younger than 70 years old in lower-income countries than in higher-income countries (about 50% vs 15%-20%, respectively). The global direct medical costs of hypertension are estimated at $370 billion per year, with the health care savings from effective management of blood pressure projected at roughly $100 billion per year.3 For every death from CVD, there are up to 3 other serious CVD events, which also incur medical and social costs;4 it is estimated that CVD costs 2%-4% of gross national income in low- and middle-income countries.5 Even though most CVD is preventable through simple, effective, and inexpensive interventions, control rates of blood pressure remain very low on a global scale because these interventions are underused in most of the world. Although rates of hypertension control are currently only about 14% worldwide,6 Canada, some Scandinavian countries, and some health systems in the United States have achieved control rates approaching 70%.7, 8 Pilot programs in Barbados and Malawi show that it is possible to increase control rates rapidly.9 Improved prevention and treatment have decreased mortality rates from CVD in higher-income countries, and accounted for 60% of the decline in CVD-related mortality and nearly 3 quarters of the decline in all-cause mortality in the United States between 1950 and 2000.10 Achieving similar declines worldwide would have dramatic health and economic benefits. The decline in heart disease deaths from 1980 to 2000 in the United States was roughly attributable equally to improved clinical services and prevention programs.11 The publication of updated hypertension treatment guidelines, such as the recent Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults, authored by the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and others,12 generates much needed interest in, and attention to, hypertension treatment. However, dissemination of updated treatment recommendations alone is not sufficient to improve hypertension control; rather, it is the systematic implementation of the guideline content that improves the quality of care. Effective treatment of large populations with hypertension is urgently needed now, as more than 25 000 deaths per day occur due to hypertension. To help address this public health emergency, the Resolve to Save Lives (Resolve) Cardiovascular Health Initiative has been established. Resolve is a 5-year, $225 million initiative housed at Vital Strategies, a global health non-profit organization, that will support key organizations and engage new partners to accelerate global and national action.13 Funded by Bloomberg Philanthropies, the Chan Zuckerberg Initiative, and the Bill and Melinda Gates Foundation, with global partners that include the World Health Organization (WHO), the World Bank, the CDC Foundation, and The Johns Hopkins Bloomberg School of Public Health, Resolve is focused on helping low- and middle-income countries accelerate and scale-up implementation of proven tools and strategies to prevent CVD. This is aligned with many countries' internal non-communicable disease prevention initiatives and goals and supports the United Nations Sustainable Development Goals.14 Resolve focuses on 3 key interventions to reduce CVD—improving treatment of hypertension from the current global control rate of 14% to a target of 50%, reducing current levels of sodium intake by 30%, and completely eliminating artificial trans-fat from the food supply. Improved treatment of high blood pressure, which rapidly and substantially reduces risks of stroke, heart attack, kidney damage, and other health problems, can also improve primary care as a component of a universal health coverage system. Modeling suggests that more effective control of hypertension could save more lives than any other clinical intervention,15 and that together, these 3 interventions can prevent 100 million deaths worldwide over the next 30 years. Blood pressure can be controlled in most people, and improving hypertension treatment can be achieved by existing health systems through the use of inexpensive, once-daily medications.16 However, because treatment is generally life-long and patients are usually asymptomatic, achieving high levels of control is difficult. Health systems that are successful in sup

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jch.13195

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 109

Metadata

Authors
Frieden, T. R., & Jaffe, M. G.
Venue
The Journal of Clinical Hypertension
Publisher
Wiley
Published
2018-01-25
Volume
20
Issue
2
Pages
208-211
ISSN
  • 1524-6175 (ISSN-L)
  • 1751-7176
OpenAlex
W2793202282
Cited by
109
References
11
FWCI
9.46
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.